Stem cells for the treatment of myelin loss.
Treatment of myelin loss is particularly suited to therapeutic strategies based on cell replacement. Demyelination represents a defined and functionally debilitating deficit, and remyelination can be accomplished by supplying regions of demyelination with myelinogenic cell populations. Clinical interest in stem cells as a source of myelinogenic cells arises from their ability to provide an apparently unlimited cell supply for transplantation, and from recent demonstrations that they can be directed to myelinogenic phenotypes with high purity. Here, I present the emerging perspective that stem-cell-mediated remyelination of the adult CNS is a viable therapeutic strategy, and discuss the challenges to remyelination posed by the environment of acute and chronic injuries.
Keirstead
Hans S
HS
Reeve-Irvine Research Center, Department of Anatomy & Neurobiology, School of Medicine, 2111 Gillespie Neuroscience Research Facility, University of California at Irvine, Irvine, CA 92697-4292, USA. hansk@uci.edu
D000818:Animals; D003711:Demyelinating Diseases / Q000503:physiopathology* / Q000601:surgery*; D006801:Humans; D009186:Myelin Sheath; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000639:trends*; D013234:Stem Cells; D016896:Treatment Outcome